MRK.N
Latest Trade
73.10USDChange
-0.20(-0.27%)Volume
556,877Today's Range
-
73.3152 Week Range
-
87.79As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 73.30 |
|---|---|
Open | 72.99 |
Volume | 556,877 |
3M AVG Volume | 205.30 |
Today's High | 73.31 |
Today's Low | 72.69 |
52 Week High | 87.79 |
52 Week Low | 65.26 |
Shares Out (MIL) | 2,530.32 |
Market Cap (MIL) | 184,333.50 |
Forward P/E | 11.12 |
Dividend (Yield %) | 3.57 |
Merck Says To Help Produce Johnson & Johnson's Covid-19 Vaccine
Merck Provides Update On Keytruda Indication In Metastatic Small Cell Lung Cancer In U.S.
Merck To Acquire Pandion Therapeutics
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.
Industry
Biotechnology & Drugs
Contact Info
2000 Galloping Hill Rd
KENILWORTH, NJ
07033-1310
United States
+1.908.7404000
http://www.merck.com/Executive Leadership
Kenneth C. Frazier
Chairman of the Board, President, Chief Executive Officer
Robert M. Davis
Executive Vice President, Global Services, Chief Financial Officer
Steven C. Mizell
Executive Vice President, Chief Human Resources Officer, Human Resources
Michael T. Nally
Executive Vice President, Chief Marketing Officer
Jennifer L. Zachary
Executive Vice President, General Counsel, Corporate Secretary
Price To Earnings (TTM) | 26.22 |
|---|---|
Price To Sales (TTM) | 3.84 |
Price To Book (MRQ) | 7.28 |
Price To Cash Flow (TTM) | 17.21 |
Total Debt To Equity (MRQ) | 125.57 |
LT Debt To Equity (MRQ) | 100.17 |
Return on Investment (TTM) | 11.22 |
Return on Equity (TTM) | 8.05 |
The United States will have enough COVID-19 vaccine for every American adult by the end of May, President Joe Biden said on Tuesday after Merck & Co agreed to make rival Johnson & Johnson's inoculation.
Merck & Co Inc will help make rival Johnson & Johnson's single-shot COVID-19 vaccine, the Washington Post reported on Tuesday, citing senior officials from U.S. President Joe Biden's administration.
Merck & Co said on Thursday that U.S. regulators have asked for additional data beyond the Phase III study already conducted in order to support potential emergency use authorization of its experimental COVID-19 drug MK-7110.
Merck & Co said on Thursday that U.S. regulators have asked for additional data beyond the Phase III study already conducted in order to support potential emergency use authorization of its experimental COVID-19 drug MK-7110.
Merck & Co Inc said on Thursday it would buy drug developer Pandion Therapeutics Inc for about $1.85 billion in cash, expanding its portfolio of drugs that target autoimmune diseases.
Merck & Co Inc said on Thursday it would buy drug developer Pandion Therapeutics Inc for $1.85 billion, to expand its portfolio of drugs that target autoimmune diseases. (Reporting by Manas Mishra in Bengaluru; Editing by Ramakrishnan M.)
Merck & Co Inc said on Wednesday it was in talks with governments and companies to potentially help with manufacturing of COVID-19 vaccines that have been already authorized.
Merck & Co Inc has agreed to acquire drugmaker OncoImmune in a deal that will give it control of a drug that could help ease symptoms and reduce deaths in patients with severe or critical cases of COVID-19.
Merck & Co Inc is in talks with governments and companies to potentially help with manufacturing COVID-19 vaccines that have been already authorized, the Wall Street Journal reported on Wednesday.
Merck & Co Inc said on Thursday Ken Frazier, one of only a handful of Black executives leading major U.S. companies, will step down as chief executive officer at the end of June and be replaced by Chief Financial Officer Robert Davis.
Drugmaker Merck & Co Inc on Thursday said its analysis of available data does not support the safety and efficacy of its anti-parasite drug, ivermectin, for the treatment of COVID-19.
U.S. drugmaker Merck & Co Inc said on Thursday it was expecting early data from a trial of the experimental antiviral drug it was developing with Ridgeback Bio as early as the first quarter.
Merck & Co Inc said on Thursday Kenneth Frazier, one of only a handful of Black executives leading major U.S. companies, will step down as chief executive officer at the end of June and be replaced by Chief Financial Officer Robert Davis.
Merck & Co Inc said on Thursday Kenneth Frazier, one of only a handful of Black executives leading major U.S. companies, will step down as chief executive officer at the end of June and be replaced by Chief Financial Officer Robert Davis.
Merck & Co said on Thursday Chief Executive Officer Kenneth Frazier will retire and will be replaced by Chief Financial Officer Robert Davis. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)
U.S. Treasury prices rose, pushing benchmark 10-year yields to a three-week low on Monday, as risk appetite ebbed after drugmaker Merck ended its COVID-19 vaccine program and amid persistent worries about surging virus cases and their potential for prolonged lockdowns. Yields...
The Nasdaq opened at a record high on Monday as markets geared up for a busy week of earnings from mega-cap technology firms, while the Dow and S&P 500 came under pressure from a decline in Merck's shares.
Drugmaker Merck & Co said on Monday it would stop development of its two COVID-19 vaccines and focus pandemic research on treatments, with initial data on an experimental oral antiviral expected by the end of March.
Drugmaker Merck & Co on Monday said it will end development of its two COVID-19 vaccines, and will focus pandemic research on treatments, with initial efficacy data on an experimental oral antiviral expected by the end of March.
The U.S. Supreme Court on Tuesday rejected Merck & Co Inc's bid to revive a $2.54 billion jury verdict it won against rival drugmaker Gilead Sciences Inc for infringing a patent in a dispute over a blockbuster hepatitis C treatment.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.